PHAT Phathom Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1783183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY86.8%
TTM net income YoY69.8%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
FCF margin-7.7%
EBITDA margin-9.1%
Returns
ROE—
ROA-28.4%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets200.8%
Debt / equity—
Current ratio1.76x
Interest coverage-0.41x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-21.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $175.11M | $55.25M |
| Cost of revenue | $22.60M | $7.97M |
| Gross profit | $152.51M | $47.28M |
| R&D expense | $32.78M | $34.08M |
| SG&A expense | $279.72M | $290.66M |
| Operating income | -$159.99M | -$277.47M |
| Interest expense | $68.11M | $72.01M |
| Pretax income | -$221.25M | -$334.33M |
| Income tax | $0 | $0 |
| Net income | -$221.25M | -$334.33M |
| EBITDA | -$159.35M | -$276.67M |
| EPS (basic) | -3.03 | -5.29 |
| EPS (diluted) | -3.03 | -5.29 |
| Weighted avg. shares (diluted) | 72.92M | 63.18M |
| Balance sheet | ||
| Cash & equivalents | $129.97M | $297.26M |
| Receivables | $78.13M | $38.80M |
| Inventory | $5.52M | $3.21M |
| Current assets | $228.97M | $360.13M |
| PP&E, net | $1.06M | $1.48M |
| Total assets | $259.15M | $378.32M |
| Current liabilities | $132.04M | $85.73M |
| Short-term debt | $0 | $0 |
| Long-term debt | $209.09M | $201.41M |
| Total debt | $209.09M | $201.41M |
| Total liabilities | $697.32M | $631.90M |
| Shareholders' equity | -$438.17M | -$253.58M |
| Net debt | $79.11M | -$95.85M |
| Shares outstanding | 71.42M | 68.52M |
| Cash flow statement | ||
| Operating cash flow | -$166.78M | -$266.77M |
| Capital expenditure | $229,000 | $135,000 |
| Free cash flow | -$167.00M | -$266.90M |
| Investing cash flow | -$229,000 | -$135,000 |
| Financing cash flow | -$288,000 | $182.77M |
| Depreciation & amortization | $633,000 | $795,000 |
| Stock-based compensation | $28.72M | $24.05M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.